Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease
Public ClinicalTrials.gov record NCT01019694. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Patient Acceptability of Ipratropium Bromide/Albuteroll Delivered by the Respimat® Inhaler in Adults With Chronic Obstructive Pulmonary Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to evaluate long-term safety and patient acceptability of COMBIVENT RESPIMAT Inhalation Spray as compared to the COMBIVENT Inhalation Aerosol Chlorofluorocarbon-Metered Dose Inhaler (CFC-MDI) and the free combination of ATROVENT Hydrofluoroalkane (HFA) and albuterol Hydrofluoroalkane (HFA) inhalation aerosols.
Study identification
- NCT ID
- NCT01019694
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 470 participants
Conditions and interventions
Conditions
Interventions
- Combivent CFC-MDI Drug
- Combivent Respimat 20/100 mcg Drug
- Atrovent HFA 42 mcg + Albuterol HFA 200 mcg Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2009 (Type not available)
- Primary completion
- Apr 2011 (Actual)
- Completion
- Not listed
- Last update posted
- Oct 23, 2014
Started 2009
United States locations
- U.S. sites
- 55
- U.S. states
- 26
- U.S. cities
- 50
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1012.62.153 Boehringer Ingelheim Investigational Site | Jasper | Alabama | — | — |
| 1012.62.145 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 1012.62.156 Boehringer Ingelheim Investigational Site | Mesa | Arizona | — | — |
| 1012.62.135 Boehringer Ingelheim Investigational Site | Berkeley | California | — | — |
| 1012.62.141 Boehringer Ingelheim Investigational Site | Riverside | California | — | — |
| 1012.62.155 Boehringer Ingelheim Investigational Site | Boulder | Colorado | — | — |
| 1012.62.126 Boehringer Ingelheim Investigational Site | Fort Collins | Colorado | — | — |
| 1012.62.131 Boehringer Ingelheim Investigational Site | Wheat Ridge | Colorado | — | — |
| 1012.62.144 Boehringer Ingelheim Investigational Site | Stamford | Connecticut | — | — |
| 1012.62.123 Boehringer Ingelheim Investigational Site | Waterbury | Connecticut | — | — |
| 1012.62.114 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1012.62.124 Boehringer Ingelheim Investigational Site | DeLand | Florida | — | — |
| 1012.62.139 Boehringer Ingelheim Investigational Site | Pensacola | Florida | — | — |
| 1012.62.134 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1012.62.115 Boehringer Ingelheim Investigational Site | Winter Park | Florida | — | — |
| 1012.62.146 Boehringer Ingelheim Investigational Site | Decatur | Georgia | — | — |
| 1012.62.113 Boehringer Ingelheim Investigational Site | Coeur d'Alene | Idaho | — | — |
| 1012.62.157 Boehringer Ingelheim Investigational Site | Dubuque | Iowa | — | — |
| 1012.62.159 Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| 1012.62.116 Boehringer Ingelheim Investigational Site | Lafayette | Louisiana | — | — |
| 1012.62.148 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 1012.62.137 Boehringer Ingelheim Investigational Site | North Dartmouth | Massachusetts | — | — |
| 1012.62.132 Boehringer Ingelheim Investigational Site | Ann Arbor | Michigan | — | — |
| 1012.62.117 Boehringer Ingelheim Investigational Site | Livonia | Michigan | — | — |
| 1012.62.158 Boehringer Ingelheim Investigational Site | Minneapolis | Minnesota | — | — |
| 1012.62.127 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1012.62.129 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1012.62.147 Boehringer Ingelheim Investigational Site | Cherry Hill | New Jersey | — | — |
| 1012.62.149 Boehringer Ingelheim Investigational Site | Summit | New Jersey | — | — |
| 1012.62.112 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| 1012.62.111 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 1012.62.107 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1012.62.120 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1012.62.150 Boehringer Ingelheim Investigational Site | Toledo | Ohio | — | — |
| 1012.62.103 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1012.62.104 Boehringer Ingelheim Investigational Site | Pittsburgh | Pennsylvania | — | — |
| 1012.62.154 Boehringer Ingelheim Investigational Site | East Providence | Rhode Island | — | — |
| 1012.62.128 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1012.62.130 Boehringer Ingelheim Investigational Site | Easley | South Carolina | — | — |
| 1012.62.151 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1012.62.161 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 1012.62.109 Boehringer Ingelheim Investigational Site | Greer | South Carolina | — | — |
| 1012.62.118 Boehringer Ingelheim Investigational Site | Spartanburg | South Carolina | — | — |
| 1012.62.125 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 1012.62.140 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 1012.62.143 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1012.62.152 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 1012.62.102 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 1012.62.122 Boehringer Ingelheim Investigational Site | Danville | Virginia | — | — |
| 1012.62.119 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1012.62.142 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 1012.62.108 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1012.62.133 Boehringer Ingelheim Investigational Site | Spokane | Washington | — | — |
| 1012.62.105 Boehringer Ingelheim Investigational Site | Tacoma | Washington | — | — |
| 1012.62.101 Boehringer Ingelheim Investigational Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01019694, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 23, 2014 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01019694 live on ClinicalTrials.gov.